RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorHenry M. Jackson Foundation for the Advancement of Military Medicine
About this trial
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
Eligibility criteria
Qualifiers
Thai National
Age ≥18 and ≤60 years of age
Can read and write Thai
Able and willing to provide written informed consent
Disqualifiers
Weight <50 kg or > 115 kg
Presence of HLA B*57:01 allele associated with viral control.
Anyone with contraindication to intramuscular injections, placement of intravenous lines, and blood draws
Acute or serious illness requiring systemic treatment and/or hospitalization within 90 days prior to entry.
Trial design
Treatments tested in this trial
- VRC07-523LS
- PGDM1400LS
- ChAdOx1.tHIVconsv1
- ChAdOx1.HIVconsv62
- MVA.tHIVconsv4
- A244d11 gp120
- ALFQ
- Placebo
Treatment groups
48 Participants
are divided into 3 treatment groupsSponsors and collaborators
Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead sponsor
US Military HIV Research Program
Collaborator
Source ClinicalTrials.gov